 NEW YORK, July 29, 2021 GLOBE NEWSWIRE -- SIGA Technologies, Inc. SIGA NASDAQ: SIGA, a commercial-stage pharmaceutical company focused on the health security market, today announced that it has entered into a collaboration with Oxford University in the United Kingdom UK to provide TPOXX tecovirimat under an expanded access protocol to treat individuals affected by monkeypox in the Central African Republic CAR. Under the agreement, Oxford University will sponsor the protocol and study in CAR, and SIGA will provide up to 500 courses of TPOXX tecovirimat at no cost. 